Efficacy of Immunization with a Combination of Serum and Recombinant Hepatitis B Vaccines

Pearl, Karlyn K.; Ortiz, Ana A.; Pearl, William

doi:10.1086/646783

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been 2 studies evaluating the immunogenicity and the protective efficacy of combined vaccination. [101,102] The first concluded that the booster effect of RV was inferior to that of PDV in healthcare workers who had received 2 doses of PDV. It was also suggested that there might be an accelerated decline in anti-HBs when different vaccines were used in combination.…”

Section: Use Of Plasma-derived and Recombinant Vaccines In Combinationmentioning

confidence: 99%

“…It was also suggested that there might be an accelerated decline in anti-HBs when different vaccines were used in combination. [101] Another study demonstrated that a combined vaccination with PDV and RV was both protective and immunogenic in infants. [102] The protective efficacy of combined vaccination in high-risk infants ranged from 89 to 93%, similar to that in other reports using either PDV or RV (table I).…”

Section: Use Of Plasma-derived and Recombinant Vaccines In Combinationmentioning

confidence: 99%

“…PDV was used at a dose of 20μg in the former study, [101] while 5μg of PDV was used in the latter study. [102] Therefore, the above-mentioned differences in results can be attributed to different doses of vaccine used.…”

Section: Use Of Plasma-derived and Recombinant Vaccines In Combinationmentioning

confidence: 99%

See 2 more Smart Citations

Practical Considerations in Converting from Plasma-Derived to Recombinant Hepatitis B Vaccines

Lee

1998

BioDrugs

View full text Add to dashboard Cite

Plasma-derived and recombinant vaccines have been developed to prevent hepatitis B virus infections. Both types of vaccine perform very well with respect to safety, immunogenicity and protective efficacy. The protection afforded by both types of vaccine is satisfactory for at least 5 to 10 years after vaccination, and a further booster dose is not necessary during this period. However, the plasma-derived vaccine is costly to produce and there is an unjustified but prevalent fear that it may be contaminated by potential pathogens. The supply of human plasma for production of the plasma-derived vaccine cannot be assured once use of hepatitis B vaccines becomes universal. It is therefore inevitable that the recombinant vaccine will replace the plasma-derived vaccine. If necessary, both vaccines can be used in combination. Future directions for hepatitis B vaccine development include: determination of the need for incorporation of pre-S gene products to enhance immunogenicity; defining a practical strategy to combat the problem of escape mutants after vaccination; and development of combination vaccines containing other inactivated antigens to allow complete immunisation against several diseases with a minimal number of injections.

show abstract

Section: Use Of Plasma-derived and Recombinant Vaccines In Combinationmentioning

confidence: 99%

Section: Use Of Plasma-derived and Recombinant Vaccines In Combinationmentioning

confidence: 99%

See 1 more Smart Citation

Practical Considerations in Converting from Plasma-Derived to Recombinant Hepatitis B Vaccines

Lee

1998

BioDrugs

View full text Add to dashboard Cite

show abstract

A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants

Lee

Huang

et al. 1995

Vaccine

View full text Add to dashboard Cite

Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19

Agurto-Arteaga

Poma-Acevedo²,

Rios-Matos³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Within the framework of the current COVID-19 pandemic, there is a race against time to find therapies for the outbreak to be controlled. Since vaccines are still tedious to develop and partially available for low-income countries, passive immunity based on egg-yolk antibodies (IgY) is presented as a suitable approach to preclude potential death of infected patients, based on its high specificity/avidity/production yield, cost-effective manufacture, and ease of administration. In the present study, IgY antibodies against a recombinant RBD protein of SARS-CoV-2 were produced in specific-pathogen-free chickens and purified from eggs using a biocompatible method. In vitro immunoreactivity was tested, finding high recognition and neutralization values. Safety was also demonstrated prior to efficacy evaluation, in which body weight, kinematics, and histopathological assessments of hamsters challenged with SARS-CoV-2 were performed, showing a protective effect administering IgY intranasally both as a prophylactic treatment or a post-infection treatment. The results of this study showed that intranasally delivered IgY has the potential to both aid in prevention and in overcoming COVID-19 infection, which should be very useful to control the advance of the current pandemic and the associated mortality.

show abstract

Efficacy of Immunization with a Combination of Serum and Recombinant Hepatitis B Vaccines

Cited by 3 publications

References 5 publications

Practical Considerations in Converting from Plasma-Derived to Recombinant Hepatitis B Vaccines

Practical Considerations in Converting from Plasma-Derived to Recombinant Hepatitis B Vaccines

A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants

Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19

Contact Info

Product

Resources

About